GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » YoY EPS Growth

MaxCyte (LSE:MXCT) YoY EPS Growth : 21.98% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. MaxCyte's YoY EPS Growth for the quarter that ended in Mar. 2024 was 21.98%.

MaxCyte's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was £-0.07.


MaxCyte YoY EPS Growth Historical Data

The historical data trend for MaxCyte's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte YoY EPS Growth Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.60 28.00 -25.40 -19.62 -54.50

MaxCyte Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -203.33 -21.54 -67.92 2.44 21.98

MaxCyte YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

MaxCyte's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.292--0.189)/ | -0.189 |
=-54.50 %

MaxCyte's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.071--0.091)/ | -0.091 |
=21.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of MaxCyte's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (LSE:MXCT) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

MaxCyte (LSE:MXCT) Headlines

From GuruFocus

MaxCyte to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By GuruFocusNews GuruFocusNews 05-13-2022

MaxCyte to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 06-01-2023

MaxCyte to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 05-03-2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By GuruFocusNews GuruFocusNews 04-15-2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By GuruFocusNews GuruFocusNews 07-02-2022

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

By sperokesalga sperokesalga 03-27-2023